查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1715627

甲状腺眼疾药物市场依治疗类型、给药途径、类型、诊断、最终使用者和分布划分－2025-2030 年全球预测

Thyroid Eye Disease Treatments Market by Treatment Type, Route of Administration, Type, Diagnosis, End-User, Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

甲状腺眼疾治疗市场规模预计在 2024 年为 26.7 亿美元，预计在 2025 年增长至 28.3 亿美元，复合年增长率为 5.94%，预计在 2030 年达到 37.8 亿美元。

主要市场统计数据
基准年2024年 26.7亿美元
预计2025年 28.3亿美元
预测年份 2030 37.8亿美元
复合年增长率（%） 5.94%

甲状腺眼疾 (TED) 既具有临床复杂性，又具有不断发展的治疗机会，这些机会正在重塑医疗保健提供者管理这种具有挑战性的疾病的方式。近年来，在理解​​潜在病理和实施多种治疗策略（从保守的医疗干预到手术治疗）方面取得了显着进展。本执行摘要深入探讨了 TED 治疗的多方面前景，详细介绍了重新定义患者照护的科学进步和策略见解。本介绍将重点放在当前护理环境的关键方面，强调治疗和诊断方法的创新如何影响临床决策和改善患者的治疗效果。随着研究的深入和新治疗方法的出现，相关人员正在见证临床实践的转变，这需要可靠的分析和策略远见。不断发展的治疗方法凸显了需要一种综合的观点，不仅要考虑生物和临床因素，还要考虑塑造治疗模式的市场动态和监管驱动因素。这项详细的审查为决策者提供了开创性的概述，并为后续章节的更深入理解和策略讨论铺平了道路。

重新定义甲状腺眼疾治疗前景的转捩点

近年来，在科学创新和市场动态的推动下，甲状腺眼疾治疗模式发生了重大变革时期。先进的影像技术和增强的诊断通讯协定改变了临床医生诊断和分类 TED 的方式，从而可以更早进行干预并製定更有针对性的治疗策略。标靶治疗的出现，特别是在免疫调节和生物製药领域，反映了向个人化医疗的更广泛转变。这些进步与对微创手术的日益重视相结合，以补充传统的医疗方法。随着临床实践的发展，经济考量和医疗保健政策将进一步影响治疗选择和研发投资。这种转变不仅改变了治疗方法组合，也拓宽了病患管理的范围，并整合了内分泌科医生、眼科医师和外科专家之间的多学科合作。生态系统的全面转变凸显了技术整合、策略伙伴关係和监管适应的关键作用。这种情况要求该领域的领导者将策略愿景与创新相结合，以解决未满足的需求并提高护理的有效性和品质。这种动态环境需要采取积极主动的方法来适应快速变化并利用新的研究和临床机会。

关键细分洞察助力目标定位策略

仔细分析市场区隔可以揭示对于制定有针对性且有效的 TED 治疗策略至关重要的详细结构。在考虑治疗类型时，市场明确区分医疗介入和外科手术介入。在医疗领域，已经详细分析了各种治疗方法，包括皮质类固醇、免疫抑制剂、单株抗体、甲状腺激素调节剂和蛋白酪氨酸激酶抑制剂。相反，手术治疗策略包括眼睑手术、眼眶减压术和斜视手术。除了治疗方式外，给药途径（静脉注射、口服或局部）也被视为决定疗效和病人依从性的关键因素。此外，根据疾病类型（I 型 TED 和 II 型 TED）对市场进行细分，可以更清楚地制定干预措施。诊断技术形成另一个关键的细分层，透过血液检查、影像检查、眼眶超音波、放射性碘摄取测试等各种测试来追踪市场。分析涵盖最终用户，从医院和门诊中心到专科诊所，每个用户都带来了独特的机会和挑战。最后，分销通路发挥关键作用，医院药局网路、网路药局、传统零售药局等监督市场。细分的每个方面都有助于描述化合物，不仅阐明了当前的趋势，而且还指导了未来的研究、投资决策和临床策略。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球甲状腺疾病的发生率和盛行率不断上升，迫切需要有效的治疗方法。
      • 提高医疗保健专业人员对甲状腺眼疾症状和治疗方法的认识
    • 限制因素
      • 甲状腺眼疾治疗产品频繁召回引发担忧
    • 机会
      • 製药公司与研究机构持续合作，强化甲状腺眼疾治疗
      • 甲状腺眼疾治疗的创新带来新的和更好的治疗方法
    • 任务
      • 目前治疗甲状腺眼疾的药物的潜在副作用和不良反应
  • 市场区隔分析
    • 治疗类型：患者越来越需要透过手术治疗来恢復视觉功能和美观。
    • 给药途径：静脉注射因其有效性和作用速度而更受青睐。
    • 类型：甲状腺眼疾药物在治疗 I 型 TED 中抑制发炎和防止进展的重要性
    • 诊断：眼眶超音波由于其非侵入性和成本效益而变得越来越重要。
    • 最终用户：随着对便利、经济有效的治疗方案的需求不断增长，门诊中心越来越多地采用甲状腺眼疾药物
    • 配送：无缝取得专科护理使得医院药局变得越来越重要
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 甲状腺眼疾治疗市场（依治疗类型）

  • 治疗
    • 皮质类固醇
    • 免疫抑制剂
    • 单株抗体
    • 甲状腺激素控制
    • 蛋白酪氨酸激酶抑制剂
  • 手术治疗
    • 眼睑手术
    • 眼眶减压手术
    • 斜视手术

7. 甲状腺眼疾治疗市场（依给药途径）

  • 静脉
  • 口服
  • 话题

8. 甲状腺眼疾治疗市场（依类型）

  • I型TED
  • II型TED

9. 甲状腺眼疾治疗市场（依诊断）

  • 血液检查
  • 影像检查
  • 眼眶超音波
  • 放射性碘摄取量测试

第 10 章 甲状腺眼疾治疗市场（依最终使用者）

  • 医院
  • 门诊中心
  • 专科诊所

第11章 甲状腺眼疾治疗市场（依分布）

  • 医院药房
  • 网路药局
  • 零售药局

12.美洲甲状腺眼疾治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

13.亚太甲状腺眼疾药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

14.欧洲、中东和非洲甲状腺眼疾药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • ACELYRIN, INC.
  • Amgen Inc.
  • argenx SE
  • Bausch & Lomb Incorporated
  • Biocon Limited
  • BioXpress Therapeutics SA
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Hetero Drugs Limited
  • Immunovant, Inc.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson Services Inc.
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sling Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viridian Therapeutics, Inc.
Product Code: MRR-033332D2AF77

The Thyroid Eye Disease Treatments Market was valued at USD 2.67 billion in 2024 and is projected to grow to USD 2.83 billion in 2025, with a CAGR of 5.94%, reaching USD 3.78 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.67 billion
Estimated Year [2025] USD 2.83 billion
Forecast Year [2030] USD 3.78 billion
CAGR (%) 5.94%

Thyroid eye disease (TED) presents both clinical complexities and evolving therapeutic opportunities that are reshaping the manner in which healthcare providers manage this challenging condition. Over recent years, remarkable progress has been made in understanding the underlying pathology and implementing diverse treatment strategies, from conservative medical interventions to surgical remedies. This executive summary delves into the multifaceted landscape of TED treatments, detailing the scientific advances and strategic insights that have redefined patient care. In this introductory section, the focus is on framing the critical aspects of the current treatment environment, highlighting how innovations in therapy and diagnostic methodologies are influencing clinical decisions and improving patient outcomes. As research deepens and new treatment modalities emerge, stakeholders are witnessing a transformation in clinical practice that demands robust analysis and strategic foresight. The evolution in therapeutic approaches underscores the necessity of an integrative perspective-one that not only considers the biological and clinical factors but also the market dynamics and regulatory drivers that shape treatment paradigms. This detailed exploration serves as a ground-breaking overview for decision-makers, paving the way for a deeper understanding and strategic discussion throughout the subsequent sections.

Transformative Shifts Redefining the Thyroid Eye Disease Treatment Landscape

In recent years, the landscape of thyroid eye disease treatment has undergone significant transformative shifts, driven by both scientific innovations and changing market dynamics. Advanced imaging technologies and enhanced diagnostic protocols have reshaped how clinicians diagnose and classify TED, enabling earlier intervention and more tailored treatment strategies. The emergence of targeted therapies, particularly in the realm of immunomodulatory and biologic treatments, reflects a broader shift toward personalized medicine. These advances are coupled with a growing emphasis on minimally invasive surgical procedures that complement traditional medical treatments. As clinical practices evolve, economic considerations and healthcare policies further influence treatment selections and investment in research and development. This transformation is not only altering the therapeutic mix but also broadening the scope of patient management, integrating multi-disciplinary collaborations between endocrinologists, ophthalmologists, and surgical experts. The comprehensive changes within this ecosystem highlight the critical role of technological integration, strategic partnerships, and regulatory adaptations. In this context, leaders in the field are urged to align their strategic vision with innovations that address unmet needs and improve both the efficacy and quality of care. This dynamic environment demands a proactive approach to adapt to rapid changes and to harness emerging opportunities in research and clinical practice.

Key Segmentation Insights Informing Targeted Strategies

A careful dissection of market segmentation reveals a detailed structure that is crucial for crafting targeted and effective strategies for TED treatments. When considering treatment types, the market distinctly differentiates between medical and surgical interventions. The medical treatment arm is meticulously analyzed through a spectrum of therapies that include corticosteroids, immunosuppressants, monoclonal antibodies, agents for thyroid hormone control, and tyrosine kinase inhibitors. Conversely, surgical treatment strategies are further explored through procedures such as eyelid surgery, orbital decompression surgery, and strabismus surgery. In tandem with treatment modality, the route of administration-a key determinant of both efficacy and patient compliance-has been scrutinized in terms of intravenous, oral, and topical applications. Additionally, segmenting the market by disease type, namely between Type I TED and Type II TED, offers further clarity in tailoring interventions. Diagnostic methodologies form another important segmentation layer that tracks the market through various tests including blood tests, imaging tests, orbital ultrasound, and radioactive iodine uptake tests. Analysis extends to the end-user dimension, where care settings span from hospitals and outpatient centers to specialty clinics, each presenting unique opportunities and challenges. Finally, distribution channels play a critical role, with market oversight including hospital pharmacy networks, online pharmacies, and traditional retail pharmacies. Each segmentation facet contributes to a compounding narrative that not only illuminates current trends but also directs future research, investment decisions, and clinical strategies.

Based on Treatment Type, market is studied across Medical Treatment and Surgical Treatment. The Medical Treatment is further studied across Corticosteroids, Immunosuppressants, Monoclonal Antibodies, Thyroid Hormone Control, and Tyrosine Kinase Inhibitors. The Surgical Treatment is further studied across Eyelid Surgery, Orbital Decompression Surgery, and Strabismus Surgery.

Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.

Based on Type, market is studied across Type I TED and Type II TED.

Based on Diagnosis, market is studied across Blood Test, Imaging Test, Orbital Ultrasound, and Radioactive Iodine Uptake Test.

Based on End-User, market is studied across Hospitals, Outpatient Centers, and Specialty Clinics.

Based on Distribution, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.

Key Regional Insights Shaping Global Market Dynamics

The TED treatment market is characterized by distinct regional variations, reflecting both local healthcare infrastructure and regional economic dynamics. In the Americas, robust healthcare spending, coupled with strong research and development initiatives, creates a fertile ground for innovation and rapid adoption of advanced therapeutic modalities. Meanwhile, Europe, Middle East & Africa experience a blend of mature healthcare markets and emerging opportunities, driven by a careful balance between tradition and innovation. European nations, in particular, continually enhance diagnostic technologies and treatment protocols, while markets in the Middle East and Africa adapt rapidly to dynamic demand patterns through strategic partnerships and policy reforms. The Asia-Pacific region stands out with its fast-growing healthcare infrastructure and increasing investment in research, making it a pivotal arena for both new market entrants and established players. These regional insights underscore the critical need for tailored strategies that address local demands while leveraging global best practices. Interregional differences in regulatory frameworks, reimbursement policies, and patient preferences remain at the core of strategic decision-making processes that drive market growth and innovation.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New Jersey, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights Highlighting Competitive Landscape and Innovation

The competitive arena of thyroid eye disease treatment is populated by a diverse group of key companies that drive innovation, invest in advanced research, and expand their market presence. Market leaders including Abbott Laboratories, AbbVie Inc., ACELYRIN, INC., Amgen Inc., argenx SE, and Bausch & Lomb Incorporated are at the forefront of developing novel therapeutic interventions and enhancing patient care. In addition, companies such as Biocon Limited, BioXpress Therapeutics SA, Cipla Limited, and Dr. Reddy's Laboratories Ltd. continue to push the boundaries of both medical and surgical treatment options. Prominent names such as Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline PLC, and H. Lundbeck A/S reaffirm the commitment to robust innovation pipelines and targeted clinical solutions. Hetero Drugs Limited, Immunovant, Inc., Intas Pharmaceuticals Ltd., and Johnson & Johnson Services Inc. bring to the table significant advancements and an acute understanding of market needs. The competitive landscape is further enriched by Lupin Limited, Merck KGaA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sling Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Viridian Therapeutics, Inc., each contributing distinct approaches that range from breakthrough therapies to enhanced surgical techniques. This confluence of expertise reinforces the industry's multifaceted approach in addressing the clinical complexities of thyroid eye disease and sets the stage for future growth and competitive differentiation.

The report delves into recent significant developments in the Thyroid Eye Disease Treatments Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ACELYRIN, INC., Amgen Inc., argenx SE, Bausch & Lomb Incorporated, Biocon Limited, BioXpress Therapeutics SA, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline PLC, H. Lundbeck A/S, Hetero Drugs Limited, Immunovant, Inc., Intas Pharmaceuticals Ltd., Johnson & Johnson Services Inc., Lupin Limited, Merck KGaA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sling Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Viridian Therapeutics, Inc.. Actionable Recommendations for Navigating the Transformative Market

Industry leaders are encouraged to adopt a proactive and strategic approach in order to capitalize on the rapidly transforming landscape of thyroid eye disease treatments. Stakeholders should prioritize investment in innovative therapeutic research, particularly in the sphere of targeted biologics and minimally invasive surgical techniques. Given the nuanced segmentation across treatment types, routes of administration, disease types, and diagnostic protocols, it is essential to develop tailored strategies that address individual patient profiles and local market dynamics. Emphasis should be placed on integrating advanced diagnostic tools and data analytics into routine clinical practice, which not only improves precision but also facilitates early intervention. Furthermore, forging robust strategic alliances, both on a regional and cross-regional level, can help in pooling expertise and expediting the adoption of best practices. There is a clear imperative for optimizing distribution networks to ensure timely accessibility of therapies, alongside streamlining processes within hospital and online pharmacy channels. Overall, a deepened focus on understanding market segmentation, regional disparities, and the competitive landscape will provide industry leaders with the insights needed to mitigate risk and harness the substantial opportunities inherent in this evolving therapeutic domain.

Conclusion: Embracing a Future of Innovation and Personalized Care

In conclusion, the landscape of thyroid eye disease treatments is characterized by a dynamic interplay between innovation, strategic market segmentation, and evolving regional dynamics. As stakeholders navigate the complex therapeutic ecosystem, it is imperative to consider the diversity of treatment modalities, ranging from cutting-edge medical interventions to refined surgical techniques. The in-depth segmentation analysis - encompassing treatment type, route of administration, disease classification, diagnostic methodology, end-user setting, and distribution channels - has revealed not only the intricacies of current practices but also the directions for future innovation and strategic planning. Moreover, regional insights indicate that while the Americas and Europe, Middle East & Africa provide robust infrastructure and progressive policy environments, the Asia-Pacific market offers immense potential with its rapid expansion and increasing research investments. Coupled with the competitive drive of leading companies, the market is poised for transformative growth that prioritizes personalized care and data-driven decision making. This comprehensive review underscores the necessity for adaptability and strategic foresight among clinicians, manufacturers, and policy makers, all of whom play pivotal roles in shaping the future of TED treatment paradigms.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising global incidence and prevalence of thyroid disorders necessitates effective treatment options
      • 5.1.1.2. Increasing awareness about symptoms and treatments for thyroid eye disease among healthcare providers
    • 5.1.2. Restraints
      • 5.1.2.1. Concern associated with frequent product recalls of thyroid eye disease treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing collaborations between pharmaceutical companies and research institutions enhancing thyroid eye disease treatment product
      • 5.1.3.2. Rising advancements in innovation of thyroid eye disease treatment to enhance novel therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Potential side effects and adverse reactions associated with current thyroid eye disease treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Increasing need for surgical treatments to restore visual function and cosmetic appearance among patients
    • 5.2.2. Route of Administration: Rising preference for intravenous administration owing to efficacy and immediate relief
    • 5.2.3. Type: Significant importance of thyroid eye disease treatments for treating type I TED for controlling inflammation and preventing progression
    • 5.2.4. Diagnosis: Increasing significance for orbital ultrasound owing to its non-invasive appeal and cost-effectiveness
    • 5.2.5. End-User: Expanding adoption of thyroid eye disease treatments across outpatient centers with rising need for convenient and cost-effective treatment solutions
    • 5.2.6. Distribution: Growing importance of hospital pharmacies owing to seamless access to specialized treatments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Thyroid Eye Disease Treatments Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medical Treatment
    • 6.2.1. Corticosteroids
    • 6.2.2. Immunosuppressants
    • 6.2.3. Monoclonal Antibodies
    • 6.2.4. Thyroid Hormone Control
    • 6.2.5. Tyrosine Kinase Inhibitors
  • 6.3. Surgical Treatment
    • 6.3.1. Eyelid Surgery
    • 6.3.2. Orbital Decompression Surgery
    • 6.3.3. Strabismus Surgery

7. Thyroid Eye Disease Treatments Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral
  • 7.4. Topical

8. Thyroid Eye Disease Treatments Market, by Type

  • 8.1. Introduction
  • 8.2. Type I TED
  • 8.3. Type II TED

9. Thyroid Eye Disease Treatments Market, by Diagnosis

  • 9.1. Introduction
  • 9.2. Blood Test
  • 9.3. Imaging Test
  • 9.4. Orbital Ultrasound
  • 9.5. Radioactive Iodine Uptake Test

10. Thyroid Eye Disease Treatments Market, by End-User

  • 10.1. Introduction
  • 10.2. Hospitals
  • 10.3. Outpatient Centers
  • 10.4. Specialty Clinics

11. Thyroid Eye Disease Treatments Market, by Distribution

  • 11.1. Introduction
  • 11.2. Hospital Pharmacy
  • 11.3. Online Pharmacy
  • 11.4. Retail Pharmacy

12. Americas Thyroid Eye Disease Treatments Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Thyroid Eye Disease Treatments Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Thyroid Eye Disease Treatments Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Sling Therapeutics reveals advance phase 2b/3 trial results for linsitinib in thyroid eye disease management
    • 15.3.2. Acelyrin, Inc. announces new Phase 2 data and Phase 3 plans for lonigutamab in treating thyroid eye disease
    • 15.3.3. Lundbeck launches advance clinical trial of CD40L blocker Lu AG22515 targeting thyroid eye disease
    • 15.3.4. Amgen announced TEPEZZA approval in Japan marks a significant advancement in thyroid eye disease treatment
    • 15.3.5. Viridian Therapeutics enhances with Phase III trials of VRDN-003 for treating thyroid eye disease
    • 15.3.6. Verana Health announces launch of Qdata thyroid eye disease
    • 15.3.7. Xeris Biopharma finalizes worldwide licensing agreement for Xeriject teprotumumab in thyroid eye disease treatment
    • 15.3.8. Viridian Therapeutics partners with Ypsomed AG to enhance subcutaneous thyroid eye disease treatment
    • 15.3.9. Amgen completes acquisition of Horizon Therapeutics to expand rare disease treatment portfolio
    • 15.3.10. Tourmaline Bio announces FDA clearance of Investigational New Drug application for TOUR006
  • 15.4. Strategy Analysis & Recommendation
    • 15.4.1. Sling Therapeutics, Inc.
    • 15.4.2. Amgen Inc.
    • 15.4.3. Viridian Therapeutics, Inc. by miRagen Therapeutics, Inc.
    • 15.4.4. ACELYRIN, INC.

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. ACELYRIN, INC.
  • 4. Amgen Inc.
  • 5. argenx SE
  • 6. Bausch & Lomb Incorporated
  • 7. Biocon Limited
  • 8. BioXpress Therapeutics SA
  • 9. Cipla Limited
  • 10. Dr. Reddy's Laboratories Ltd.
  • 11. Eli Lilly and Company
  • 12. F. Hoffmann-La Roche AG
  • 13. Genmab A/S
  • 14. GlaxoSmithKline PLC
  • 15. H. Lundbeck A/S
  • 16. Hetero Drugs Limited
  • 17. Immunovant, Inc.
  • 18. Intas Pharmaceuticals Ltd.
  • 19. Johnson & Johnson Services Inc.
  • 20. Lupin Limited
  • 21. Merck KGaA
  • 22. Novartis AG
  • 23. Pfizer, Inc.
  • 24. Regeneron Pharmaceuticals, Inc.
  • 25. Sling Therapeutics, Inc.
  • 26. Teva Pharmaceutical Industries Ltd.
  • 27. Viridian Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. THYROID EYE DISEASE TREATMENTS MARKET MULTI-CURRENCY
  • FIGURE 2. THYROID EYE DISEASE TREATMENTS MARKET MULTI-LANGUAGE
  • FIGURE 3. THYROID EYE DISEASE TREATMENTS MARKET RESEARCH PROCESS
  • FIGURE 4. THYROID EYE DISEASE TREATMENTS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. THYROID EYE DISEASE TREATMENTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. THYROID EYE DISEASE TREATMENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. THYROID EYE DISEASE TREATMENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THYROID EYE DISEASE TREATMENTS MARKET DYNAMICS
  • TABLE 7. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY THYROID HORMONE CONTROL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY EYELID SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL DECOMPRESSION SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STRABISMUS SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE I TED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE II TED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMAGING TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OUTPATIENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA THYROID EYE DISEASE TREATMENTS